Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation Safety, Pharmacokinetic and Pharmacodynamic Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2018
At a glance
- Drugs AMXT 1501+DFMO (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Aminex Therapeutics
- 12 Jun 2018 Planned End Date changed from 15 Dec 2019 to 12 Jun 2018.
- 12 Jun 2018 Planned primary completion date changed from 1 Jun 2019 to 12 Jun 2018.
- 12 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.